NASDAQ: CYCN
Cyclerion Therapeutics Inc Stock Ownership - Who owns Cyclerion Therapeutics?

Insider buying vs selling

Have Cyclerion Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Peter M. HechtDirector2025-03-25181,818$2.75
$500.00kBuy
Michael J. 1. HigginsDirector2025-03-259,090$2.75
$25.00kBuy
Slate Path Capital LP10% Owner2024-11-21357,880$1.55
$555.07kSell

1 of 1

CYCN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CYCN insiders and whales buy or sell their stock.

CYCN Shareholders

What type of owners hold Cyclerion Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Terrance McGuire28.46%771,191$2.08MInsider
Amy W. Schulman23.38%633,625$1.71MInsider
Peter M. Hecht20.65%559,760$1.51MInsider
Andreas Busch9.40%254,704$687.70kInsider
Mark G. Currie9.29%251,648$679.45kInsider
Tyndall Capital Partners L P6.08%164,777$444.90kInstitution
Siren LLC4.29%116,155$313.62kInstitution
Regina Margaret Graul3.70%100,303$270.82kInsider
William Huyett2.49%67,590$182.49kInsider
Christopher I. Wright1.58%42,728$115.37kInsider

1 of 3

CYCN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CYCN11.83%88.17%Net SellingNet Buying
BCDA0.06%99.94%Net BuyingNet Buying
ACXP6.40%11.67%Net Buying
TRAW4.36%95.64%Net BuyingNet Buying
PMCB8.75%16.40%

Cyclerion Therapeutics Stock Ownership FAQ

Who owns Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ: CYCN) is owned by 14.09% institutional shareholders, 105.00% Cyclerion Therapeutics insiders, and 0.00% retail investors. Terrance McGuire is the largest individual Cyclerion Therapeutics shareholder, owning 771,191.00 shares representing 28.46% of the company. Terrance McGuire's Cyclerion Therapeutics shares are currently valued at $2.31M.

If you're new to stock investing, here's how to buy Cyclerion Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.